Global Pharmaceutical & Biotechnology Outlook 2013 Japan Pharma - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.

Global Pharmaceutical & Biotechnology Outlook 2013 Rising Stars - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/10016/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Rising-Stars/

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long.

Global Pharmaceutical & Biotechnology Outlook 2013 Mature Biotech - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/10017/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Mature-Biotech/

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma.